About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT01674972

Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls

The incretin effect is impaired in patients with type 2 diabetes mellitus (T2DM), thus GLP-1 receptor agonists are used for the treatment of T2DM. Insulin resistance is a pathophysiologic hallmark of ...

Lead sponsor: University Hospital, Basel, Switzerland•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University Hospital, Basel, Switzerland

Primary endpoint: GLP-1 response to oral glucose Secondary endpoints: glucose and insulin responses to oral glucose challenge

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Biopsy proven NAFLD or NASH

Exclusion Criteria

•additional concomitants liver disease
•T2DM
•alcohol consumption \>40g/d for male subjects and \>20g/d for female subjects

Related studies

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

NCT05463796 · Cancer Risk, Cancer Predisposition Syndrome, and more

Active Not RecruitingPhase 2

Comparative Study Between Febuxostat Versus Vitamin E in Non-alcoholic Steatohepatitis Patients With Hyperuricemia

NCT05574036 · Non Alcoholic Steatohepatitis, Hyperuricemia

Active Not RecruitingPhase 2

Efficacy and Safety of Pemafibrate for Nonalcoholic Fatty Liver Disease

NCT06623539 · Non Alcoholic Fatty Liver Disease

COMPLETEDPhase 2

Comparison of Effectiveness of Obeticholic Acid With Vitamin E in Patients of Non-alcoholic Fatty Liver Disease

NCT07104786 · Non Alcoholic Fatty Liver Disease

COMPLETEDPhase 2

A Phase 2b Study of Icosabutate in Fatty Liver Disease

NCT04052516 · Non Alcoholic Steatohepatitis (NASH)

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 29, 2012Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment102

Start dateJan 2011

Last updatedAug 29, 2012

Condition

Non Alcoholic Fatty Liver Disease Non Alcoholic Steatohepatitis

Locations shown

University Hospital Basel, Division of Gastroenterology and Hepatology

Basel

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 29, 2012Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions